

Partnering Activity Update

Feb 1, 2021

Cautionary Notes

Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.

Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:

- (i) failures in new product development***
- (ii) changes in general economic conditions due to reform of medical insurance system***
- (iii) failures in obtaining the expected results due to effects of competing products or generic drugs***
- (iv) infringements of the Company's intellectual property rights by third parties***
- (v) stagnation of product supply from the delay in production due to natural disasters, fires and so on***
- (vi) onset of new side effect of post-licensure medical product***
- and, (vii) currency exchange rate fluctuations and interest rate trend.***

Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.



Partnering Activity (2010~) (1)

As of Jan 25, 2021

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Sep 2010	KYPROLIS (Carfilzomib)	Multiple Myeloma (Proteasome inhibitor)	L	L	Amgen, USA (in-license/JPN)
Sep 2011	CORALAN (Ivabradine)	Chronic Heart Failure (HCN channel blocker)	L	L	Servier, France (in-license/JPN)
	PARSABIV (Etelcalcetide)	Secondary Hyperparathyroidism (Calcium sensing receptor agonist)	L	L	Amgen, USA (in-license/JPN)
	OPDIVO (Nivolumab)	Melanoma, NSCLC, RCC, Hodgkin's Lymphoma, H&N Cancer, Gastric Cancer, Malignant pleural mesothelioma , Colorectal cancer (MSI-H), Esophageal cancer (Anti-PD-1 mAb)	L	L	BMS, USA (out-license/except JPN, KOR & TWN)
	ORENCIA (Abatacept)	Rheumatoid Arthritis Juvenile Idiopathic Arthritis (T cell activation inhibitor)	L	L	BMS, USA (in-license/JPN)
Apr 2013	ONGENTYS (Opicapone)	Wearing-off phenomenon in Parkinson's Disease (COMT inhibitor)	L	L	Bial, Portugal (in-license/JPN)
Oct 2013	DEMSEER (Metyrosine)	Status of Catecholamine Excess Secretion in Pheochromocytoma (Tyrosine hydroxylase inhibitor)	L	L	Bausch Health, USA (in-license/JPN)

Partnering Activity (2010~) (2)

As of Jan 25, 2021

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Dec 2013	FORXIGA (Dapagliflozin)	Type 2 Diabetes, Type 1 Diabetes, Chronic Heart Failure (SGLT-2 inhibitor)	L	L	AstraZeneca, UK (in-license/JPN)
		Chronic Kidney Disease (SGLT-2 inhibitor)	Filing	Filing	
Jul 2014	OPDIVO (Nivolumab)	Melanoma, NSCLC, RCC, Hodgkin's Lymphoma, H&N Cancer, Gastric Cancer, Malignant pleural mesothelioma , Colorectal cancer (MSI-H), Esophageal cancer (Anti-PD-1 mAb)	L	L	BMS, USA (out-license/JPN, KOR & TWN)
	ONO-4578	Solid Tumors (EP4 antagonist)	I	I/II	
	YERVOY (Ipilimumab)	Melanoma, RCC, Colorectal cancer (MSI-H), NSCLC (Anti-CTLA-4 mAb)	L	L	BMS, USA (in-license/JPN, KOR & TWN)
	ONO-4483 (Lirilumab)	Solid Tumors (Anti-KIR mAb)	I	I/II	
	ONO-4482 (Relatlimab)	Melanoma (Anti-LAG-3 mAb)	I/II	II/III	
	ONO-4686 BMS-986207	Solid Tumors (Anti-TIGIT mAb)	I/II	I/II	
	ONO-7701 (Linrodostat)	Bladder Cancer (IDO1 inhibitor)	III	III	
	ONO-7807 BMS-986258	Solid Tumors (Anti-TIM3 mAb)	I/II	I/II	



Partnering Activity (2010~) (3)

As of Jan 25, 2021

Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Jul 2014	ONO-7911 (Bempegaldesleukin)	Solid Tumors (PEGylated IL-2)	I	I/II	BMS, USA (in-license/JPN, KOR & TWN)
		Melanoma, RCC (PEGylated IL-2)	—	III	
	OPALMON (Limaprost α-CD)	Lumber Spinal Canal Stenosis (oral PGE1 analogue)	L	L	Meiji Seika Pharma, JPN (out-license/THA)
Dec 2014	VELEXBRU (Tirabrutinib)	Primary central nervous system lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma (BTK inhibitor)	L	—	Gilead Sciences, USA (out-license/except JPN, KOR, TWN, CHN & ASEAN)
		Pemphigus (BTK inhibitor)	II	—	
		Generalized scleroderma (BTK inhibitor)	I	—	
		B Cell Lymphoma (BTK inhibitor)	—	II	
Mar 2016	ONO-9054 (Sepetaprost)	Glaucoma Ocular Hypertension (FP/EP3 dual receptor agonist)	II	II	Santen Pharmaceutical, JPN (out-license/World-wide)
May 2017	MEKTOVI (Binimetinib)	BRAF-mutant Melanoma (MEK inhibitor · BRAF inhibitor)	L	L	Pfizer, USA (in-license/JPN & KOR)
	BRAFTOVI (Encorafenib)	BRAF-mutant Colorectal Cancer (MEK inhibitor · BRAF inhibitor)	L	L (BRAFTOVI)	



Partnering Activity (2010~) (4)

As of Jan 25, 2021


Date	Product name or Code number (Generic name)	Indication (MOA)	Phase (JP)	Phase (Overseas)	Partner (Agreements)
Aug 2017	ONO-5704 SI-613 (Diclofenac etalhyaluronate)	Osteoarthritis (Combined drug of hyaluronic acid and NSAID)	Filing	II	Seikagaku, JPN (in-license/JPN)
		Enthesopathy (Combined drug of hyaluronic acid and NSAID)	II	—	
Jun 2019	ONO-7912 CPI-613 (Devimistat)	Pancreatic Cancer Acute Myeloid Leukemia (Cancer metabolism inhibitor)	I	III	Rafael Pharmaceuticals, USA (in-license/JPN, KOR, TWN & ASEAN)
Jul 2019	ONO-7913 (Magrolimab)	Non-Hodgkin's Lymphoma Acute Myeloid Leukemia Ovarian Cancer, Colorectal Cancer (Anti-CD47 mAb)	I	II	Gilead Sciences, USA (in-license/JPN, KOR, TWN & ASEAN)
		Myelodysplastic syndromes (Anti-CD47 mAb)	I	III	
Oct 2020	ONO-2017 (Cenobamate)	Partial-onset seizures (voltage-gated sodium currents inhibitor, γ-aminobutyric acid (GABA _A) ion channel modulator)	III	L	SK Biopharmaceuticals, Korea (in-license/JPN)
Dec 2020	ONO-7018 (CTX-177)	Malignancies of lymphocytes (mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor)	Pre-clinical	Pre-clinical	Chordia Therapeutics, Japan (in-license/Global)



Collaboration with BMS for OPDIVO®

**Start collaboration
in May 2005**


**Expand collaboration
in Sep 2011**




Strategic Alliance with BMS in JP, KR & TW

- To Strengthen Immuno-oncology Portfolio
- To Accelerate Combination Therapies

Co-development




Co-promotion




Development
cost share

Profit/loss
allocation



Collaboration with BMS for ORENZIA®

- Novel Biologic Inhibiting Upstream Inflammation in RA



Collaboration with AstraZeneca for FORXIGA®

- The First SGLT-2 Inhibitor in the World for Type-2 Diabetes
- In 2019, additional approval for Type-1 diabetes in Japan
- In 2020, additional approval for Chronic Heart Failure in Japan

